Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 4(65), 2021
DOI: 10.1128/aac.02338-20
Links
Tools
Activity of Cefepime in Combination with the novel ß-Lactamase inhibitor taniborbactam (VNRX-5133) against ESBL-producing isolates in in vitro checkerboard assays
Journal article published in 2021 by
Wendy Kloezen,
Ria J. Melchers,
Panagiota-Christina Georgiou,
Johan W. Mouton,
Joseph Meletiadis 
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Data provided by 
Abstract
Extended-spectrum-β-lactamase (ESBL)-producing strains are increasing worldwide, limiting therapeutic options. Taniborbactam (VNRX-5133) is a newly developed β-lactamase inhibitor with a wide spectrum of activity covering both serine and metallo enzymes.